Q-Med Launches Modified Sodium Hyaluronate In China
This article was originally published in PharmAsia News
Executive Summary
Swedish-based Q-Med has launched its modified sodium hyaluronate for injection in China. After five years of clinical trial and investigation, the product received approval from China's State FDA at the end of last year. It represents the only approved hyaluronic acid filler for cosmetic and plastic surgery purposes in the country. Q-Med has marketed the subcutaneous filler in more than 70 countries and regions worldwide, including the U.S., Canada, Australia, India, Korea and Singapore, safely treating 10 million cases. (Click here for more - Chinese Language)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.